TABLE 1.
Baseline characteristics.
| Variables | Total (n = 180) | Group D+C (n = 90) | Group D+M (n = 90) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 92 (51.11) | 49 (54.44) | 43 (47.78) |
| Female | 88 (48.89) | 41 (45.56) | 47 (52.22) |
| Age (months), M (Q1, Q3) | 31.00 (21.00, 41.00) | 31.00 (22.25, 41.00) | 29.50 (21.00, 39.75) |
| Weight (kg), M (Q1, Q3) | 13.00 (11.30, 15.00) | 13.00 (11.50, 15.00) | 13.00 (11.07, 14.50) |
| Body temperature (°C), M (Q1, Q3) | 36.60 (36.40, 36.73) | 36.60 (36.42, 36.70) | 36.60 (36.40, 36.80) |
| ASA, n (%) | |||
| I | 19 (10.56) | 9 (10.00) | 10 (11.11) |
| II | 161 (89.44) | 81 (90.00) | 80 (88.89) |
| Fasting time (h), M (Q1, Q3) | 2.51 (1.92, 4.35) | 2.91 (1.77, 5.61) | 2.41 (1.96, 3.98) |
| Previous sedation history, n (%) | 28 (15.56) | 13 (14.44) | 15 (16.67) |
| Primary diagnosis, n (%) | |||
| Routine health examination | 8 (4.44) | 4 (4.44) | 4 (4.44) |
| Respiratory system disorders | 102 (56.67) | 49 (54.44) | 53 (58.89) |
| Neurological disorders | 17 (9.44) | 12 (13.33) | 5 (5.56) |
| Digestive system disorders | 6 (3.33) | 2 (2.22) | 4 (4.44) |
| Cardiovascular disorders | 35 (19.44) | 15 (16.67) | 20 (22.22) |
| Sensory system disorders | 12 (6.67) | 8 (8.89) | 4 (4.44) |
| Examination types, n (%) | |||
| Pulmonary function test | 94 (52.22) | 44 (48.89) | 50 (55.56) |
| Magnetic resonance imaging (MRI) | 5 (2.78) | 3 (3.33) | 2 (2.22) |
| Electroencephalography (EEG) | 10 (5.56) | 8 (8.89) | 2 (2.22) |
| Hearing screening | 11 (6.11) | 7 (7.78) | 4 (4.44) |
| Electrocardiography (ECG) | 19 (10.56) | 8 (8.89) | 11 (12.22) |
| Specialized ultrasonography | 33 (18.33) | 16 (17.78) | 17 (18.89) |
| Computed tomography (CT) | 8 (4.44) | 4 (4.44) | 4 (4.44) |
Data are presented as median (interquartile range) or number (%), as appropriate.
Abbreviations: Group D+C received intranasal dexmedetomidine combined with oral chloral hydrate, and Group D+M received intranasal dexmedetomidine combined with oral midazolam.